Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research and Development, Neurosciences

Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research
                        and Development, Neurosciences

PR Newswire

BERLIN, BOSTON and MUMBAI, India, May 7, 2013

BERLIN, BOSTON and MUMBAI, India, May 7, 2013 /PRNewswire/ -- Piramal Imaging
SA, a division of Piramal Enterprises, today announced Ana M. Catafau, M.D.,
Ph.D., has joined the company as vice president (VP) of Clinical Research and
Development, Neurosciences.

(Logo: http://photos.prnewswire.com/prnh/20130507/NE09018LOGO)

Dr. Catafau's appointment comes on the heels of Piramal Imaging's announcement
that the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) have accepted the company's applications for review of the
investigational positron emission tomography (PET) amyloid imaging agent [18F]
florbetaben.

"Early detection of beta amyloid plaque is important as the build-up is a
potential indication that a patient could be at risk for developing dementia,
cognitive impairment and Alzheimer's disease," said Dr. Catafau. "With the
recent submission of florbetaben to the FDA and EMA, I am joining the company
at an exciting time. I look forward to working with the Piramal team and to
help bring to market an agent that may have the power to safely detect beta
amyloid plaques prior to onset of significant cognitive decline."

"The molecular imaging community will benefit from Piramal's strong pipeline
and focus on the research and development of new PET tracers. There is a clear
need, particularly in the neurosciences, for PET tracers for many targets, and
this applies both to clinical practice and pharmaceutical drug development. In
my new role, I will work closely with Piramal's enthusiastic and extremely
competent team on the advancement of the field of molecular neuroimaging,"
added Dr. Catafau.

Dr. Catafau brings more than 20 years of experience in neuroimaging research
with SPECT and PET both in academia and in the pharmaceutical industry. Her
tenure includes 16 years with the University Hospitals Clinic and Sant Pau in
Barcelona, and eight years at GlaxoSmithKline. Most recently, Dr. Catafau was
the President and CEO of Barcelona Imaging Group, S.L. (BIG).

Dr. Catafau is an internationally recognized expert in the field of
neuroimaging, having been the Chair of the European Association of Nuclear
Medicine (EANM) Neuroimaging Committee, a member of the Journal of Nuclear
Medicine Editorial Board and a member of scientific committees of
international congresses. Her experience is backed up by her extensive
scientific publication records, numerous grants, contracts, and scientific
awards won related to her work with brain imaging.

"As we look to commercialize our first product in the field of molecular
neuroimaging, it was natural that we create a new leadership position to lead
clinical research and development in neurology," said Andrew Stephens, VP of
Clinical Research and Development at Piramal Imaging. "Dr. Catafau's wealth of
scientific knowledge combined with her clinical and strong leadership
experience makes her the ideal for this role."

About Piramal Imaging SA

Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in
2012 with the acquisition of the molecular imaging research and development
portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular
imaging, Piramal Imaging is focusing on a key field of modern medicine.
Piramal Imaging strives to be a leader in the Molecular Imaging field by
developing innovative products that improve early detection and
characterization of chronic and life threatening diseases leading to better
therapeutic outcomes and improved quality of life. For more information please
go to http://piramalenterprises.com.

About Piramal Enterprises Ltd.

Piramal Enterprises is one of India's largest diversified companies with
operations in pharmaceuticals, financial services and information management.
Piramal Enterprises generated consolidated revenues of $500 million in the
2012 financial year. In the pharmaceuticals field, Piramal Enterprises is one
of the leading custom manufacturing players in the world and operates in the
global critical-care segment with a portfolio of inhalation and injectable
anesthetics. Its OTC business is ranked number 7 in India. PEL is also
involved in drug discovery & research and has strong pipeline of development
products. In the financial services field, PEL has a real-estate-focused PE
fund called Indiareit, and an NBFC that focuses on lending to the real-estate
and education sector. Recently, PEL also entered the global
information-management industry by acquiring the US-based company Decision
Resources Group. PEL acquired the global rights to a molecular-imaging
research and development portfolio from Bayer AG. The portfolio includes the
rights to [^18F] florbetaben, a highly specialized molecule used in PET
imaging to detect beta-amyloid in the brain, a widely recognized marker for
Alzheimer's disease.

For media inquiries, please contact:



Tammy Best

Marketing Communications Manager

Piramal Enterprises – Imaging Division

Contact: +1 617-725-0070 x408

tammy.best@piramal.com



Akansha Pradhan

Corporate Communications

Piramal Group

Contact: +91 3351 4082

akansha.pradhan@piramal.com



SOURCE Piramal Imaging

Website: http://piramalenterprises.com/
 
Press spacebar to pause and continue. Press esc to stop.